Buckingham Strategic Partners Neurocrine Biosciences Inc Transaction History
Buckingham Strategic Partners
- $8.25 Billion
- Q3 2025
A detailed history of Buckingham Strategic Partners transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Buckingham Strategic Partners holds 13,263 shares of NBIX stock, worth $1.92 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
13,263
Previous 5,252
152.53%
Holding current value
$1.92 Million
Previous $660,000
181.97%
% of portfolio
0.02%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NBIX
# of Institutions
725Shares Held
102MCall Options Held
230KPut Options Held
477K-
Black Rock Inc. New York, NY14.2MShares$2.06 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.71MShares$1.41 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.56MShares$805 Million0.45% of portfolio
-
Jpmorgan Chase & CO New York, NY4.73MShares$685 Million0.04% of portfolio
-
State Street Corp Boston, MA4.35MShares$630 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.9B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...